advertisement
Advances in Therapy 24
Showing records 1 to 24 | Display all abstracts in Advances in Therapy69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Sato S
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Nakano T
Advances in Therapy 2016; 33: 1452-1459
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Kawase K
Advances in Therapy 2016; 33: 1612-1627
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Quaranta L
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Inoue R
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Biagioli E
Advances in Therapy 2016; 33: 1305-1315
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Hirooka K
Advances in Therapy 2016; 33: 1628-1634
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Vittitow JL; Weinreb RN
Advances in Therapy 2016; 33: 1612-1627
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Galli F
Advances in Therapy 2016; 33: 1305-1315
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Nitta E
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Kimura T
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Poli D
Advances in Therapy 2016; 33: 1305-1315
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Araie M
Advances in Therapy 2016; 33: 1612-1627
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Ukegawa K
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Suzumura H
Advances in Therapy 2016; 33: 1452-1459
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Tsujikawa A
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Tanino T
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Rulli E
Advances in Therapy 2016; 33: 1305-1315
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Advances in Therapy 2016; 33: 1612-1627
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Riva I
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Yamazaki Y
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Hollander L
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Yoshikawa K; Tatemichi M
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Katsanos A; Longo A; Uva MG; Torri V; Weinreb RN
Advances in Therapy 2016; 33: 1305-1315
